Philips Debuts Noninvasive Ventilator With High Flow Therapy to Improve Patient Care

Amsterdam (ots/PRNewswire) -

- Philips V60 Plus ventilator receives CE Mark, expands on
Philips' commitment and leadership in hospital respiratory care
- New comprehensive solution enhances clinician workflow and
maximizes equipment efficiency to help drive earlier intervention
in respiratory distress

Royal Philips (https://www.philips.com/) (NYSE: PHG) (AEX: PHIA),
a global leader in health technology, today announced the Philips V60
Plus ventilator has received CE mark approval. This comprehensive
solution expands on Philips' noninvasive ventilation (NIV) gold
standard platform, integrating both NIV and high flow therapy (HFT)
in a single device. Clinicians can rapidly adjust therapies around
constantly changing patient conditions without having to switch
devices. Designed for early intervention in respiratory failure, the
V60 Plus enables clinicians to further enhance patient outcomes with
less invasive respiratory care therapies, while improving clinician
workflow and maximizing equipment investments.

(Photo:
https://mma.prnewswire.com/media/786730/Philips_V60_Plus.jpg )

(Photo: https://mma.prnewswire.com/media/786731/V60_Plus.jpg )

Patients with acute respiratory failure require immediate
attention from caregivers. While early implementation with NIV is
associated with less endotracheal intubation, as well as the
reduction of serious complications and adverse events in the ICU [1],
clinicians sometimes face challenges when weaning patients off of
this therapy. The V60 Plus now delivers a wide range of non-invasive
support for these patients, which supports clinicians to begin the
weaning process sooner. By having the different, but complementary
modes in one device, the V60 Plus can simplify both workflow and
device availability.

"When treating respiratory patients in Intensive and Emergency
Care settings, it's critical for clinicians to be able to wean
efficiently or to quickly escalate care depending on their patient's
condition and specific needs. This often means complex workflows and
alternating devices in time-sensitive situations," said Jim Alwan,
Business Leader of Philips Hospital Respiratory Care. "We are excited
to offer a comprehensive noninvasive solution that enables quick
therapy and interface transitions, so clinicians can focus on
providing for their patients while spending less time setting up
equipment."

"We are delighted with the high flow function of the V60 Plus,"
says Peter Lindberg, R.N., Leader NIV Program at St. Goran Hospital
in Stockholm, Sweden. "It saves us a lot of time and space as we can
use the same equipment for both NIV and high flow. When you need to
wean patients from NIV to HFT, it is very simple with the one device.
Additionally, the cannula is high quality, easy to adjust, soft
against the patient's skin and V60 flow is much quieter than our
standalone high flow system."

This solution expands on Philips' commitment and leadership in
hospital respiratory care. The V60 Plus has received CE mark and is
available for sale in Europe, and the U.S. Food and Drug
Administration (FDA) 510k has been submitted. For more information on
Philips' full suite of hospital respiratory care solutions, visit htt
ps://www.usa.philips.com/healthcare/solutions/hospital-respiratory-ca
re.

[1] Complications of non-invasive ventilation techniques: a
comprehensive qualitative review of randomized trials. M. Carron, U.
Freo et al., British Journal of Anaesthesia, June, 2013.

About Royal Philips

Royal Philips (NYSE: PHG) (AEX: PHIA) is a leading health
technology company focused on improving people's health and enabling
better outcomes across the health continuum from healthy living and
prevention, to diagnosis, treatment and home care. Philips leverages
advanced technology and deep clinical and consumer insights to
deliver integrated solutions. Headquartered in the Netherlands, the
company is a leader in diagnostic imaging, image-guided therapy,
patient monitoring and health informatics, as well as in consumer
health and home care. Philips generated 2017 sales of EUR 17.8
billion and employs approximately 77,000 employees with sales and
services in more than 100 countries. News about Philips can be found
at http://www.philips.com/newscenter.

ots Originaltext: Royal Philips
Im Internet recherchierbar: http://www.presseportal.de

Contact:
, please contact:
Kathy O'Reilly
Philips Group Press Office
Tel: +1-978-221-8919
Email: kathy.oreilly@philips.com
Twitter: @kathyoreilly
Ingrid Mitchell
Monitoring Analytics and Therapeutic Care
Tel: +1-978-482-5949
Email: ingrid.e.mitchell@philips.com

Original-Content von: Royal Philips, übermittelt durch news aktuell